Talk:SB-649,915

This is the talk page for discussing improvements to the SB-649,915 article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Pharmacology Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Low	This article has been rated as Low-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about SB-649,915.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Incongruence of alleged autoreceptor activity with other well-studied models.

The sole source cited in this article alleges that SB-649,915 acts as a 5-HT autoreceptor antagonist, thereby inhibiting release of serotonin. Unless someone can find an article stating that 5-HT1 autoreceptors are atypical, then this assertion is entirely erroneous. Caffeine, an adenosine autoreceptor antagonist, works by inhibiting the detection of adenosine (ATP leftovers, in a way) and thereby increasing the homeostatic levels of adenosine, which in turn mildly stimulates most kinds of energetic cellular activity (activity that consumes ATP or any of its relative compounds). Under this well-studied logical paradigm, any typical autoreceptor antagonist would increase the homeostatic levels of the hormone whose autoreceptor is under blockade, not decrease. This is a logical flaw that should be corrected in the interest of correctness. — Preceding unsigned comment added by 70.112.251.139 (talk) 06:51, 23 February 2012 (UTC)[reply]